Hans Bishop

Previous Founder, President, and CEO of Juno Therapeutics, acquired by Celgene in 2018 for $11B, Hans has over 30 years of experience in the biotechnology industry and has held leadership Hans Bishop has served as a member of Lyell Immunopharma’s board of directors since August 2018. Since December 2021, Mr. Bishop has also served as the Board Co-Chair and President of Altos Labs, a private life sciences company. From July 2019 to September 2021, Mr. Bishop served as the Chief Executive Officer of GRAIL, a private life sciences company, and from July 2013 to March 2018, Mr. Bishop served as President and Chief Executive Officer at Juno Therapeutics, a company that he co-founded and was acquired by Celgene. From February 2012 through July 2013, Mr. Bishop served as Executive in Residence at Warburg Pincus, a multinational private equity firm and prior to that, served as Executive Vice President and Chief Operating Officer at Dendreon, a publicly-traded cancer immunotherapy company. Mr. Bishop currently serves as the Chairman of the Board of Sana Biotechnology and as a director of Agilent Technologies, both of which are publicly traded companies, and he previously served as a director of JW Therapeutics, Juno Therapeutics, and Celgene. He received a BA in Chemistry from Brunel University in London.